Hot Value Stocks To Buy For 2019

Fred Oltarsh at Options Strategy Network explains that by understanding liquidity, implied and historical volatility, and the skew, options traders are able to build strategies to either mitigate risk or speculate in a manner that provides a reasonable opportunity for successful trading.

The first topic to understand is liquidity. The importance of liquidity is often overlooked in options trading. Whether one is trading standard or binary options, it must be clear to the trader how expensive it is to initiate and liquidate a position. The wider the bid/ask spread as a percentage of the contract value, the costlier it is to trade the particular contract. Ideally, a trader would benefit from the largest contract with the bid/ask spread at a minimum. For those who don’t focus on commissions and slippage, options traders don’t have a chance of making money in the long run.

Hot Value Stocks To Buy For 2019: Merrimack Pharmaceuticals, Inc.(MACK)

Advisors’ Opinion:

  • [By Shane Hupp]

    Here are some of the media headlines that may have effected Accern Sentiment Analysis’s rankings:

    Get Merrimack Pharmaceuticals alerts:

    Edited Transcript of MACK earnings conference call or presentation 8-May-18 12:30pm GMT (finance.yahoo.com) Investors Purchase High Volume of Merrimack Pharmaceuticals Call Options (MACK) (americanbankingnews.com) Merrimack (MACK) Reports Wider-Than-Expected Loss in Q1 (finance.yahoo.com) Merrimack Pharmaceuticals (MACK) Announces Quarterly Earnings Results, Misses Expectations By $0.05 EPS (americanbankingnews.com) Merrimack Pharmaceuticals’ (MACK) CEO Richard Peters on Q1 2018 Results – Earnings Call Transcript (seekingalpha.com)

    A number of equities analysts have issued reports on MACK shares. Robert W. Baird reiterated a “hold” rating and issued a $12.00 price objective on shares of Merrimack Pharmaceuticals in a report on Thursday, March 15th. Zacks Investment Research upgraded Merrimack Pharmaceuticals from a “hold” rating to a “buy” rating and set a $9.50 price objective for the company in a report on Wednesday, April 25th.

  • [By Lisa Levin]

    Check out these big penny stock gainers and losers

    Losers
    Aceto Corporation (NASDAQ: ACET) fell 41.9 percent to $4.30 in pre-market trading. ACETO board disclosed that it is taking proactive steps to address business and financial challenges. Canaccord Genuity downgraded Aceto from Buy to Sell.
    Helios and Matheson Analytics Inc. (NASDAQ: HMNY) fell 25.3 percent to $2.86 in pre-market trading after reporting an ATM offering of $150 million.
    Pier 1 Imports, Inc. (NYSE: PIR) fell 17.4 percent to $2.86 in pre-market trading after reporting a fourth quarter sales miss. Comps were down 7.5 percent in the quarter.
    Sleep Number Corporation (NASDAQ: SNBR) fell 12.4 percent to $32.00 in pre-market trading following a first quarter earnings miss.
    Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK) fell 10.2 percent to $11.90 in pre-market trading on news of $125 million convertible debt offering.
    Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) shares fell 8 percent to $8.02 in pre-market trading after dropping 2.02 percent on Wednesday.
    Exponent, Inc. (NASDAQ: EXPO) shares fell 5.6 percent to $80 in pre-market trading.
    Lumentum Holdings Inc. (NASDAQ: LITE) shares fell 4.8 percent to $60.00 in pre-market trading after rising 1.78 percent on Wednesday.
    vTv Therapeutics Inc. (NASDAQ: VTVT) fell 4.6 percent to $2.10 in pre-market trading after surging 84.87 percent on Wednesday.
    Taiwan Semiconductor Manufacturing Company Limited (NYSE: TSM) shares fell 4.5 percent to $40.07 in pre-market trading after the company reported Q1 results.
    Align Technology, Inc.. (NASDAQ: ALGN) fell 3.5 percent to $267.40 in pre-market trading after rising 1.61 percent on Wednesday.
    Transocean Ltd. (NYSE: RIG) shares fell 3.5 percent to $12 in pre-market trading after the company issued quarterly fleet status report.
    GoPro, Inc. (NASDAQ: GPRO) fell 3.2 percent to $4.90 in pre-market trading.
    Unilever PLC (NYSE: UL) fell 2.6 percent to $54.73 in pre-market

Hot Value Stocks To Buy For 2019: SodaStream International Ltd.(SODA)

Advisors’ Opinion:

  • [By Stephan Byrd]

    SodaStream (NASDAQ:SODA)‘s stock had its “hold” rating reiterated by stock analysts at Jefferies Group in a research note issued to investors on Wednesday. They currently have a $82.00 price target on the stock. Jefferies Group’s target price suggests a potential downside of 5.87% from the stock’s current price. Jefferies Group also issued estimates for SodaStream’s Q2 2018 earnings at $0.74 EPS, FY2018 earnings at $3.55 EPS, Q1 2019 earnings at $0.88 EPS, Q2 2019 earnings at $0.79 EPS and Q1 2020 earnings at $0.89 EPS.

  • [By Jeremy Bowman]

    I’m talking aboutSodaStream International(NASDAQ:SODA), of course, the Israeli do-it-yourself sparkling water specialist. Shares of SodaStream sold off following the earnings report on Wednesday even though the company once again beat earnings and revenue estimates. Below were the key figures from the first-quarter report.

  • [By Demitrios Kalogeropoulos]

    SodaStream(NASDAQ:SODA) recently announced surprisingly strong first-quarter earnings as sales growth sped up to a 25% pace and profitability improved. The seller of at-home carbonated beverage machines is benefiting from a long-term trend of rising global demand for sparkling water.

  • [By Chris Lange]

    SodaStream International Ltd. (NASDAQ: SODA) reported its fourth-quarter financial results before the markets opened on Wednesday. The company said that it had $1.13 in earnings per share (EPS) on $157.7 million in revenue, which compares with consensus estimates from Thomson Reuters of $0.80 in EPS on revenue of $151.57 million. In the same period of last year, it said it had EPS of $0.71 and $131.8 million in revenue.

Hot Value Stocks To Buy For 2019: ANI Pharmaceuticals, Inc.(ANIP)

Advisors’ Opinion:

  • [By Joseph Griffin]

    Canaccord Genuity set a $82.00 target price on ANI Pharmaceuticals (NASDAQ:ANIP) in a research report released on Tuesday morning. The firm currently has a buy rating on the specialty pharmaceutical company’s stock.